Home / Medicine / Cutaneous Reactions from Anti-Cancer Therapies

Cutaneous Reactions from Anti-Cancer Therapies

Edition: 1
9781975157890
ISBN/ISSN:
9781975157890
Publication Date:
February 10, 2023
2023-02-10
9781975157890
Preview link
Many oncologic therapies used to treat cancer have significant implications for the skin. These dermatologic reactions follow recognizable patterns and ...
Read More
  • Questions and Answers
  • Product Description

    Many oncologic therapies used to treat cancer have significant implications for the skin. These dermatologic reactions follow recognizable patterns and are closely related to the type of treatment given. Cutaneous Toxicities from Anti-Cancer Therapies,by Drs. Allireza Alloo and Nicole LeBoeuf, provides comprehensive coverage of cutaneous toxicities caused by the full spectrum of oncologic modes of treatment—specifically cytotoxic chemotherapy, targeted chemotherapy, and immunotherapy. This portable photoguide is a quick bedside handbook for dermatologists, oncologists, primary care providers, emergency room physicians, and other health care professionals who see patients undergoing treatment for cancer.

    • Summarizes current evidence on skin toxicity from oncologic treatment using a succinct, highly practical format for quick reference

    • Defines specific reaction patterns for oncology therapies and provides clinical pearls and treatment recommendations

    • Features abundant full-color clinical photos that help you quickly identify reaction patterns and skin toxicity from specific cancer therapies

    • Highlights special considerations for skin of color and pediatrics in boxes throughout the book
       

      Enrich Your eBook Reading Experience

    • Read directly on your preferred device(s),such as computer, tablet, or smartphone.

    • Easily convert to audiobook,powering your content with natural language text-to-speech.

  • Specs
    Edition
    1
    ISBN/ISSN
    9781975157890
    Product Format
    Paperback Book
    Trim Size
    6 x 9
    Pages
    312
    Edition
    1
    Publication Date
    February 10, 2023
  • Allireza Alloo
    NIcole LeBeouf
  • Table of contents
    CONTENTS
    Contributors vi
    oreword xi
    Introduction xii
    Part I: Special Considerations
    1. Reactions in Patients with Skin of Color . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
    2. Reactions in Pediatric Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
    Part II: Reaction Patterns
    3. Morbilliform Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
    4. Lichenoid Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
    5. Psoriasiform Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
    6. Acneiform Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
    7. Intertriginous Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
    8. Bullous Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
    9. P anniculitis- Lik e Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
    10. Purpuric Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
    11. Erythroderma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
    12. Edematous Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
    13. Sclerosing Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
    14. Pigmentary Alterations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
    15. Reactions on the Hands and Feet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
    16. Oral Toxicities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
    17. Mucositis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
    18. Hair and Nail Abnormalities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
    19. Radiation Recall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
    20. Inflamed Actinic Keratoses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
    21. Severe Cutaneous Adverse Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
    Part III: Anticancer Agents and Classes
    Section I: Cytotoxic Chemotherapy
    22. Alkylating Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
    23. Antimetabolites . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
    24. Topoisomerase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
    25. Anthracyclines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
    26. Microtubule Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
    27. Bleomycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141Section II: Targeted Agents
    28. Epidermal Growth Factor Receptor (EGFR) Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
    29. BRAF Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
    30. MEK Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
    31. PI3- Kinase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
    32. mTOR Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .170
    33. Multikinase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175
    34. BTK Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179
    35. BCR/ABL/C- Kit Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186
    36. Fibroblast Growth Factor Receptor (FGFR) Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . 192
    37. Proteasome Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197
    38. Hormonal Therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200
    39. CCR4 Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205
    Section III: Immunotherapy and Immune Modulators
    40. Cytotoxic T- Lymphocyte- Associated Protein 4 (CTLA-4) Inhibitors . . . . . . . . . . . . . . . . . 209
    41. Programmed Cell Death 1 (PD- 1)/Programmed Cell Death Ligand 1 (PD- L1)
    Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 214
    42. Thalidomide and Lenalidomide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 226
    Part IV: Other Anticancer Treatment–Associated Toxicities
    43. Radiation Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231
    44. Pruritus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235
    Appendix 245
    Photo Credits 251
    Index 253
$ 74.99 USD $74.99
*Final price may vary based on conversion rate.

PRE PUBLICATION
This product is scheduled to publish on the date provided, which is subject to change. Your order will be received, however, the item will not ship until it is available.
You will be charged when the item ships.

Quantity:
MORE OPTIONS
Item already added to cart.

Buy from another retailer

Sorry! Promocode will not apply for this product.

Customer reviews

Overall: out of 5

Sorry, we can’t add this product to your cart due to one of the following reasons:

  • This item may already be in your cart.
  • This item can’t be combined with other items in your cart.
  • Only one instance of this product can be purchased at a time.

Would you like us to update your cart with this item and proceed?

9781975157890 Cutaneous Reactions from Anti-Cancer Therapies 9781975157890 Home / Medicine / Cutaneous Reactions from Anti-Cancer Therapies 1 https://t16833-s25855.mozu.com/Cutaneous-Reactions-from-Anti-Cancer-Therapies/p/9781975157890 //cdn-tp2.mozu.com/16833-25855/cms/25855/files/f12bb8fe-3e30-4383-9948-963502d84f57 74.99 74.99 74.99 1

Your cart cannot contain products from multiple regions.
If you click continue, items in the cart from the previous region will be removed. To keep items from the previous region in your cart, click cancel.

This item is not related to current region.

AAOS members get an exclusive discount. Please click continue to log in as an AAOS member.

Sorry, we can’t add this product to your cart due to one of the following reasons:

  • This item may already be in your cart.
  • This item can’t be combined with other items in your cart.
  • Only one instance of this product can be purchased at a time.

Would you like us to update your cart with this item and proceed?